کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3087778 | 1190160 | 2015 | 8 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Suivi d'une cohorte de patients après substitution de la phénytoïne pour de la phénytoïne sodique dans un centre de lutte contre l'épilepsie
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
علم عصب شناسی
عصب شناسی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
In March 2012, the French Health Products Safety Agency interrupted the commercialization of di-hydan (phenytoin). It was replaced by diphantoïne (phenytoin sodium) and prescribers were informed that posology was equivalent for both products. We conducted a retrospective study of phenytoinemia and clinical effects comparatively for these two drugs in a population of adult patients with epilepsy admitted in La TEPPE. Forty-four patients were included. Mean age was 47.6Â years. Phenytoinemia significantly decreased after substitution (17.14Â mg/L with di-hydan versus 12.17Â mg/L with diphantoïne, PÂ <Â 8 10â6). Moreover an increase in post substitution posology of diphantoïne was noticed (264.77Â mg/L with di-hydan versus 274.73Â mg/L with diphantoïne), although not significant (PÂ =Â 0.11). Increase of seizures was non-significant (PÂ =Â 0.09). The decrease of phenytoinemia was probably due to the difference of composition between the drugs: a 100Â mg di-hydan tablet contains 100Â mg of phenytoin whereas a 100Â mg diphantoïne tablet contains 92Â mg. The specific non-linear kinetics of phenytoin reinforces this difference. A prospective study could better evaluate the risk of substituting di-hydan with diphantoïne.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Revue Neurologique - Volume 171, Issue 2, February 2015, Pages 181-188
Journal: Revue Neurologique - Volume 171, Issue 2, February 2015, Pages 181-188
نویسندگان
N. Lavandier, D. Tourniaire,